22:31:45 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Bavarian Nordic är verksamma inom biokemi. Idag är bolaget specialiserade inom utveckling, produktion och distribution av vaccin mot infektionssjukdomar i samband med cancerbehandling. Utöver huvudverksamheten framställs även vacciner mot allvarliga sjukdomar som ebola och livmoderhalscancer. Störst verksamhet återfinns inom Europa och Nordamerika, med huvudkontoret beläget i Kvistgaard.

Kalender

2022-11-09 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-09 Kvartalsrapport 2022-Q1
2022-04-06 Ordinarie utdelning BAVA 0.00 DKK
2022-04-05 Årsstämma 2022
2022-03-04 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-27 Kvartalsrapport 2021-Q1
2021-04-21 Ordinarie utdelning BAVA 0.00 DKK
2021-04-20 Årsstämma 2021
2021-03-12 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-15 Ordinarie utdelning BAVA 0.00 DKK
2020-06-12 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-27 Extra Bolagsstämma 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-04-25 Ordinarie utdelning BAVA 0.00 DKK
2019-04-24 Årsstämma 2019
2018-04-18 Ordinarie utdelning BAVA 0.00 DKK
2018-04-17 Årsstämma 2018
2017-04-26 Ordinarie utdelning BAVA 0.00 DKK
2017-04-25 Årsstämma 2017
2016-04-21 Ordinarie utdelning BAVA 0.00 DKK
2016-04-20 Årsstämma 2016
2015-04-24 Ordinarie utdelning BAVA 0.00 DKK
2015-04-23 Årsstämma 2015
2014-04-25 Ordinarie utdelning BAVA 0.00 DKK
2013-04-18 Ordinarie utdelning BAVA 0.00 DKK
2012-04-17 Ordinarie utdelning BAVA 0.00 DKK
2011-04-27 Ordinarie utdelning
2010-04-28 Ordinarie utdelning
2022-04-01 10:53:39

 

COPENHAGEN, Denmark, April 1, 2022 – In accordance with the Company’s remuneration policy, the Board of Directors of Bavarian Nordic A/S has today decided to establish new incentive programs for members of the executive and other management in the Company, including Russell Thirsk, newly appointed Executive Vice President and Chief Operating Officer.

Under the program, a total of 6,669 restricted stock units are awarded to Russell Thirsk, including matching shares which will be granted upon expiry of a 3-year period after the award date at a ratio of 1:2, i.e., one matching share will be granted for each two restricted stock units. The acquisition of restricted stock units is conditional upon the recipient not having passed away prior to the expiry of the program on April 1, 2025. The grant of matching shares is further conditioned by the recipient still being employed at expiry of the program. The value of one restricted stock unit is DKK 110.21, based on an average of the closing price of the Company's shares over a period of 15 trading days prior to today and when adjusting for matching shares.

Furthermore, in accordance with the shareholder authorization for the Board of Directors adopted as Article 5b of the Articles of Association, a new warrant program is established. A total of 81,872 warrants are granted to Russell Thirsk and other management in the Company, which entitle the warrant holders to subscribe for up to 81,872 shares in total with a nominal value of DKK 10 each at an exercise price of DKK 190.11 per share. The warrants may be exercised wholly or partly during eight fixed subscription periods, starting after the announcement of the Company’s interim results for the first half 2025. The value of each warrant equals DKK 46.55 and is calculated on the Black-Scholes model with a risk-free interest rate of 0.39 per cent and on the historical volatility of the shares. The calculation is based on a share price of DKK 171.35.

As a consequence of the aforementioned grants of restricted stock units and warrants to Executive Vice President and Chief Operating Officer, Russell Thirsk, the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameRussell Thirsk
2.Reason for the notification
a)Position/status

 
Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument


Identification code
Restricted Stock Units


DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 110.21     6,669
d)Aggregated information
  • Aggregated volume
  • Price
 

6,669
DKK 735,000.00
e)Date of the transaction2022-04-01
f)Place of the transactionOutside a trading venue

 

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameRussell Thirsk
2.Reason for the notification
a)Position/status

 
Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument


Identification code
Warrants


DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.00         63,157
d)Aggregated information
  • Aggregated volume
  • Price
 

63,157
DKK 0.00
e)Date of the transaction2022-04-01
f)Place of the transactionOutside a trading venue

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 09 / 2022